In The Wall Street Transcript William Blair’s Matt Phipps shares his outlook on what biotech industry companies he’s most closely monitoring for 2022 and the factors at play influencing his perspective sectorwide.
Equity Research
Matt Phipps Discusses Biotech Stocks With The Wall Street Transcript
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
William Blair Acts as Joint Bookrunner on Accelerant’s Initial Public Offering
William Blair acted as a joint bookrunner on a $832 million initial public offering for Accelerant Holdings (NYSE: ARX), a data-driven risk exchange connecting underwriters of specialty insurance risk with risk capital providers.
-
-